Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Attralus, Inc.
The company intends to use the series B cash to bring the first of its pan-amyloid removal (PAR) therapies into the clinic, while also advancing a diagnostic tool for systemic amyloidosis.
Private Company Edition: Neogene, Escient, ESCAPE, Resolution and Attralus raised a combined $320m in venture capital rounds. Also, large Recursion round could double the size of its pipeline, Korro Bio raised $91.5m and Flagship launched Generate Biomedicines.
- Radiopharmaceuticals, Contrast Agents
- Large Molecule